The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, ...
In 1976, cys was first used for the treatment ofcystinosis, approved by the US Food and Drug Administration (FDA), and commercialized in the 1990s [6]. Till now, cys is the only specific targeted therapy available for patients with cystinosis. The latter is a rare autosomal recessivemetab...
The near century of progress1in cancer metabolism continues to impact our understanding of oncology. Each decade has yielded new discoveries and engendered additional avenues of research and approaches to therapy. Classically, cancer metabolism has focused on central carbon metabolism, including glycolysis ...
and reviews the research and clinical research progress of metabolic diseases, cardiovascular diseases and immune-related diseases related to amino acid metabolism, in order to provide theoretical basis for targeted therapy of amino acid metabolism. ...
whether cancer cells live or die. With this knowledge, they found that reduced consumption of a specific protein building block prevents the growth of cells that become cancerous. These findings were published in the scientific journaleLifeand open up the possibility of dietary therapy for cancer....
Cancer is caused by uncontrollable growth of neoplastic cells, leading to invasion of adjacent and distant tissues resulting in death. Cancer cells have specific nutrient(s) auxotrophy and have a much higher nutrient demand compared to normal tissues. Th
Photodynamic therapy with aminolevulinic acid (ALA PDT) for oral leukoplakia has shown promising effects in regression of oral leukoplakia. Although ALA ha... SJ Wong,B Campbell,B Massey,... - 《Oral Oncology》 被引量: 19发表: 2013年 Diagnosis and management of typical and atypical lung carci...
Want to thank TFD for its existence?Tell a friend about us, add a link to this page, or visitthe webmaster's page for free fun content. Link to this page: Facebook Twitter
R. et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res. 73 (Suppl. 8), 491 (2013). Google Scholar Nayak-Kapoor, A. et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-...
Our data suggest that the expression level of these amino-acid transporters has a crucial role in the development and carcinogenesis of tumour cells, and it may be an important clinical marker of therapy for patients with tongue cancer. L-type amino-acid transporter 1 is highly expressed in ...